Alumis
Dean Dragoli has extensive work experience in the field of medicinal chemistry. Dean currently holds the position of Vice President at Alumis since June 2023. Prior to that, they were an Executive Director at Alumis from January 2022 to June 2023. Before joining Alumis, Dean worked at Ardelyx, Inc. where they served as a Senior Director from January 2021 to December 2021 and as a Director from January 2018 to January 2021. Dean also held the role of Principal Scientist at Ardelyx from June 2015 to January 2018. Earlier in their career, Dean worked at Chemocentryx, Inc. as a Scientist II from July 2012 to June 2015 and as a Senior Scientist from December 2005 to July 2012. Dean began their career at Discovery Partners International, Inc. as a Scientist II from March 2004 to December 2005, and prior to that, they worked as a Scientist from July 2001 to March 2004.
Dean Dragoli received a Bachelor of Arts degree in Chemistry from the College of the Holy Cross in 1996. Dean then went on to earn a Ph.D. in Organic Chemistry from the University of California, Berkeley from 1996 to 2001.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.